obesity drugs glp-1 news today Market Overview: GLP-1 Agonists and the Obesity Market New GLP-1 Pill Foundayo (Orforglipron)
Description
Triple agonists: Retatrutide (GIP/GLP-1/glucagon)
The next phase of GLP-1 expansion will be determined as much by manufacturing capacity and reimbursement dynamics as by clinical innovation
The most common risks of oral GLP-1s like Rybelsus, Wegovy pill, and Foundayo include : Acute pancreatitis Diabetic retinopathy complications (diabetes-related vision changes) Hypoglycemia (low blood sugar), especially when used with insulin Kidney or gallbladder issues Severe gastrointestinal reactions Allergic reactions Pulmonary aspiration during general anesthesia or deep sedation All three GLP-1s also carry a black box warning for thyroid tumors based on animal studies
This weight loss itself further improves insulin sensitivity and metabolic health
Explore the Akkermansia Microbiome Guide
Protocol for those on mid-dose tirzepatide (7.5 to 10mg) You are the most common transition candidate
